medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2012, Number 4

<< Back Next >>

Rev Invest Clin 2012; 64 (4)

Personalización del tratamiento del cáncer de pulmón de células no pequeñas

Campos-Parra AD, Cruz-Rico G, Arrieta Ó

Language: Spanish
References: 49
Page: 377-386
PDF size: 250.99 Kb.


Text Extraction

No abstract


REFERENCES

  1. Ginsberg RI, Vokes EE, Rosenzweig K. Cancer of the lung. Non small-cell lung cancer. In: De Vita VT, Hellman S, Rosenberg SA (eds.). Cancer: principles and practice of oncology. 6th. Ed. Philadelphia: Lippincott-Raven; 2001, p. 925-83.

  2. Jemal A, Siegel R, Ward E, et al. Thun. Cancer statistics. CA Cancer J Clin 2008; 58: 71-96.

  3. Herbst RS, Heymach JV, Lippman SM. Molecular origins of cancer. Lung cancer. N Engl J Med 2008; 13(359): 1367-80.

  4. Wistuba II, Mao L, Gazdar AF. Smoking molecular damage in bronchial epithelium. Oncogene 2002; 21: 7298-306.

  5. Suda K, Onozato R, Yatabe Y, Mitsudomi T. EGFR T790M mutation. A double role in lung cancer cell survival? J Thor Oncology 2009; 4(1): 1-4.

  6. Voldborg RL, Damstrup M, Spang-Thomsen H, et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997; 8(12): 1197-206.

  7. Hsuan JJ. Oncogene regulation by growth factors. Anticancer Res 1993; 13: 2521-2.

  8. Kotsakis A, Georgoulias V. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother 2010; 11(14): 1-27.

  9. Ray M, Salgia R, Everette E. The role of EGFR inhibition in the treatment of non-small cell lung cancer. VOKES the oncologist lung cancer. The Oncologist 2009; 14: 1116-30.

  10. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-81.

  11. Rosel R, Taron M, Reguart N, et al. Epidermal growth factor receptor activation: How exon 19 and21 mutations changed our understanding of the pathway. Clin Cancer Res 2006; 12(24): 7222-31.

  12. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129-39.

  13. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-91.

  14. Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer cell 2005; 7(4): 301-11.

  15. Yang XD, Jia XC, Corvalan JR, et al. Development of ABXEGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17-23.

  16. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315: 971-9.

  17. Erlotinib. CP 358774, NSC 718781, OSI 774, R 1415. Drugs R&D 2003; 4(4): 243-8.

  18. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838-48.

  19. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol 2007; 25: 1960-6.

  20. Yung WK, Vredenburgh JJ, Cloughesy TF, et al. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol 2010 [Epub ahead of print].

  21. Shepherd FA, Rodríguez-Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.

  22. Groen H, Arrieta O, Riska H, Horwood K, Mali P, Reck M. The global TRUST study of erlotinib in advanced non small-cell lung cancer (NSCLC). J Clin Oncol 2008; Suppl. 2: S3.

  23. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer– molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-44.

  24. Florescu M, Hasan B, Seymour L, et al. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J Thorac Oncol 2008; 3: 590-8.

  25. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmallcell lung cancer. J Clin Oncol 2005; 23: 5892-9.

  26. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced nonsmall-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545-52.

  27. Kris MG, Sandler A, Miller V, et al. EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial. J Clin Oncol 2005; 23: 7029.

  28. Arrieta O, Martínez-Barrera L, Treviño S, et al. Wood-smoke exposure as a response and survival predictor in Erlotinib-treated non-small cell lung cancer patients: an open label phase II study. J Thoracic Oncology 2008; 3(8): 887-93.

  29. Wheatley-Price P, Shepherd FA. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr Opin Oncol 2008; 20: 162-75.

  30. Wong MK, Lo AI, Lam B, et al. Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 2010; 65(6): 1023-8.

  31. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 4(366): 1527-37.

  32. Gatzemeier A, Ardizzoni K, Horwood J, et al., Erlotinib in non-small cell lung cancer (NSCLC): Interim safety analysis of the TRUST study. J Clin Oncol 2007; 1(25),18S: 7645.

  33. Castagnari A. Conclusions of the expert panel: importance of erlotinib as a second-line therapeutic option. BMC Proceedings 2007; 2(Suppl. 2): S4.

  34. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-67.

  35. Han SW, Kim TY, Jeon YK, et al. Optimization of patient selection for gefitinib in non-small-cell-lung-cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and akt phosphorylation. Clin Cancer Res 2006; 12(8): 2538-44.

  36. Le Calvez F, Mukeria A. Hunt JD, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 2005; 65(12): 5076-83.

  37. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med 2010; 362(25): 2380-8.

  38. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521-9.

  39. Hirsh V. Afatinib (BIBW2992 development in non-small-celllung cancer. Future Oncol 2011; 7(7): 817-25.

  40. Arrieta O, Cardona AF, Lopez AG, et al. Genotyping non-small cell lung cancer in Latinamerican patients. J Thorac Oncology 2011: 6: S325-S326.

  41. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011; 29(15): 2046-51.

  42. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004; 350: 351-60.

  43. Winton T, et al. Vinorelbine plus cosplatin vs. observation in resected non-samll cell lung cancer. N Engl J Med 2005; 352: 2589-97.

  44. Doullard JY, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol 2006; 7: 719-27.

  45. Scagliotti GV, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. J Natl Cancer Inst 2003; 95: 1453-61.

  46. Waller D, et al. Chemotherapy for patients with non-small cell lung cancer: The surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004; 26: 173-82.

  47. Pignon JP, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clinical Oncology 2008; 26(21); 3552-9.

  48. Janjigian YY, et al. Impact on disease free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J. Thorac Oncol 2011; 6: 569-75.

  49. Pennell NA, et al. A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early stage non-small cell lung cancer (NSCLC) and confirmed m mutations in the epidermal growth factor receptor (EGFR): J Clin Oncol 2011; 29 (Suppl., abst. TPS209), ASCO 2011.




2020     |     www.medigraphic.com